Identification of MTMR2 as an AML-associated candidate biomarker derived from lipid metabolism–related transcriptomic analysis
-
By
-
Chenchen Liu
-
Yueyuan Pan
-
Minggui Chen
-
Songyu Li
-
Chong Zhang
-
May 29, 2026
-
Clinical Scorecard: Discovery of MTMR2 as a Potential Biomarker Linked to Lipid Metabolism in Acute Myeloid Leukemia Through Transcriptomic Analysis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Lipid metabolism reprogramming associated with AML progression, particularly through MTMR2. |
| Target Population | |
| Care Setting | |
Key Highlights
- Exploratory analysis shows altered lipid-related clinical parameters in AML patients, including lower ApoA1 and LDL-C levels.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- M
- o
- n
- i
- t
- o
- r
-
- l
- i
- p
- i
- d
- -
- r
- e
- l
- a
- t
- e
- d
-
- c
- l
- i
- n
- i
- c
- a
- l
-
- p
- a
- r
- a
- m
- e
- t
- e
- r
- s
-
- i
- n
-
- A
- M
- L
-
- p
- a
- t
- i
- e
- n
- t
- s
- ,
-
- s
- u
- c
- h
-
- a
- s
-
- A
- p
- o
- A
- 1
-
- a
- n
- d
-
- L
- D
- L
- -
- C
-
- l
- e
- v
- e
- l
- s
- .
Risks
Patient & Prescribing Data
Lower ApoA1 and LDL-C levels, higher TG levels observed in AML patients compared to healthy controls.
Clinical Best Practices
- Incorporate lipid metabolism assessment in clinical settings alongside transcriptomic analysis.
Related Resources & Content
